



# MANAGEMENT OF PATIENTS WITH NERVE AGENT / ORGANOPHOSPHATE OR BIOLOGICAL AGENT EXPOSURE

#### **Historical Findings**

- 1. Large number of patients exhibiting signs and symptoms of nerve agent poisoning.
- 2. Circumstances provide no reason to suspect an industrial accident involving organophosphates (pesticides).
- 3. Known terrorist incident involving chemical or biological agents.

#### **Physical Findings**

1. Over stimulation of muscarinic sites increases secretions. Two acronyms which help to identify the presence of increased secretions are:

S- Salivation
L- Lacrimation
U- Urination
U- Urination
S- Salivation
U- Lacrimation
U- Urination

D- Defecation G- Gastrointestinal emptying

G- Gastrointestinal distress B- Bradycardia; Bronchiol Constriction

E- Emesis A- Abdominal effects

M- Miosis (constricted pupils)

- 2. Over stimulation of the nicotinic sites causes severe muscle twitching, cramping, and weakness.
- 3. Release of or exposure to possible biological agent

#### **Differential Diagnosis**

#### **Chemical Agent**

1. The effects caused by a mild vapor exposure, namely rhinorrhea and tightness in the chest, may easily be confused with an upper respiratory malady or allergy.





- 2. Miosis (constricted pupils), if present, will help distinguish this as a nerve agent incident, but the eyes must be examined in a very dim light to detect this.
- 3. GI symptoms from an earlier illness may be confused with those from the nerve agent effects.
- 4. Exposure to organophosphates will produce the same signs and symptoms as exposure to nerve agents.
- 5. History is the best indicator of nerve agent exposure:
  - A. Large number of patients exhibiting signs and symptoms of nerve agent poisoning.
  - B. Circumstances provide no reason to suspect an industrial accident involving organophosphates (pesticides).
  - C. Known terrorist incident.

#### **Biological Agent**

- 1. Known event involving the release of a possible biological agent.
- 2. Area Health Departments or agencies have reason to suspect a large number of people have been exposed to a biological agent and are in need of prophylactic antibiotic therapy.

#### **Protocol**

#### **General Guidelines for Chemical and Biological Incident**

- 1. Self-protection of the rescuers is the first priority. Do not rush in. Assess the situation. Be alert for secondary devices.
- 2. Remove patient from the toxic environment as quickly as possible. Emergency personnel should be dressed in the appropriate level of PPE.
- 3. Remove the patient's clothing and decontaminate the patient immediately.





#### **Specific Guidelines Related to a Chemical Incident**

- 4. Assess and secure the patient's airway and provide oxygen per the airway, oxygen and ventilation protocol.
- 5. If practical, maintain cardiac monitoring at all times.
- 6. Initiate IV access with a saline lock or 0.9 % normal saline KVO.
- 7. Medical management may include use of the following medications:
  - A. <u>Atropine</u> May be administered IV, ET or IM. Medication may be administered using a Mark 1 autoinjector (NDC 6505-01-174-9919), or medication may be in the form of 0.1 mg/ml x 10ml prefilled syringe (NDC 0000747911) or 0.4 mg/ml x 20 ml single dose vial (NDC 63323-0234-20).
  - B. <u>Pralidoxime Chloride (2-PAMCl)</u> May be administered IV or IM. Medication may be administered using a Mark 1 autoinjector (NDC 6505-01-174-9919), or medication may be in the form of a 1gram powder vial for injection (NDC 0046-0347-06).
  - C. <u>Diazepam (Valium)</u> May be administered IV or IM. Medication may be administered using a 10 mg autoinjector (NDC 6505-01-274-0951), or medication may be in the form of a 5 mg/ml single dose vial (NDC 0000041933 or 10019-005-42 or 00641-0371-25).

Since dosages needed may be higher than normally used, consult with online medical command for instructions.

6. Transport patients to a facility capable of managing a nerve agent exposure. Although field decontamination should already have been accomplished, consult with the **receiving hospitals** concerning further decontamination procedures that will be performed at their facility.

### Specific Guidelines Related to a Biological Incident

4. The need for distribution of antibiotics to the public will be determined by local health departments / agencies and use / distribution of these antibiotics will be performed only under the direction of Medical Control.





- 5. Medical management may include the use of the following medications. Choice of medications and their concentration and form will be directed by Medical Control.
  - A. <u>Ciprofloxacin</u> May be administered orally or in some cases IV. Medication may be in the form of 500 mg tablets (NDC 00026-8513-51 or 00026-8513-48), 250 mg/ml x 100 ml bottle of oral suspension (NDC 00026-8551-36) or IV solution 400 mg in D5W 200 ml bag (NDC 8527-63/00026-8).
  - B. <u>Doxycycline</u> May be administered orally or in some cases IV. Medication may be in the form of 100 mg tablets (NDC 00172-3626-70), 25 mg/5ml x 60 ml bottle of oral suspension (NDC 00069-0970-65) or 100 mg powder vial for IV use (NDC 63323-0130-10).
  - C. <u>Erythromycin</u> May be in the form of 500 mg powder vial (NDC 00074-6365-02).
  - D. <u>Gentamicin</u> May be in the form of a 40 mg/ml multi-dose vial (NDC 63323-0010-20).